|
|
News for:
|
|
For this drug, our server compiled this detailed Chemical Profile.
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
|
Click the Chemical Profile link above for detailed information.
Visit Betterchem's Drug Index for
- Exclusivity
Patents and market exclusivity
- Drug Information
Prescribing and other
information
- DMFs
Type 2 drug master files
- Databases
Free access to database search
- 21 CFR
FDA regulations for this drug
- Federal Register
FR search results for this drug
- Drug Recalls
For Rx's using this API
|
|
|
| |
FDA Approval Activities for this Drug
Dacarbazine for Injection USP, 200 mg/vial, Faulding Pharmaceutical Co. ANDA 75-940 10/18/01 4/16/03
Dacarbazine for Injection USP, 500 mg/vial, Bedford ANDA 75-812/S3 10/31/02
Dacarbazine for Injection USP, 200 mg/vial, Bedford ANDA 75-812 6/15/01 6/26/01
Dacarbazine for Injection USP, 100 mg/vial & 200 mg/vial American Pharmaceutical Partners, ANDA 75-371 8/27/99 9/2/99
Dacarbazine for Injection USP, 200 mg/vial, Gensia Sicor ANDA 75-259 DACARBAZINE Injection 100MG/VIAL DACARBAZINE AM PARTNERS
075371 DACARBAZINE Injection 200MG/VIAL DACARBAZINE AM PARTNERS
017575 DACARBAZINE Injection 100MG/VIAL DTIC-DOME BAYER 017575 DACARBAZINE Injection 200MG/VIAL DTIC-DOME BAYER 075812 DACARBAZINE Injection 200MG/VIAL DACARBAZINE Bedford 075812 DACARBAZINE Injection 500MG/VIAL DACARBAZINE Bedford 075940 DACARBAZINE Injection 200MG/VIAL DACARBAZINE Faulding 075259 DACARBAZINE Injection 200MG/VIAL DACARBAZINE Gensia Sicor 075259 DACARBAZINE Injection 500MG/VIAL DACARBAZINE Gensia Sicor
Visit Betterchem's Drug Index for FDA's latest approval information.
|
|